Selected publications
-
TBCRC009: A multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer.
Journal of Clinical Oncology.
2015
Academic Article
GET IT
Times cited: 180 -
Breast cancer risk reduction, version 2.2015 clinical practice guidelines in oncology clinical practice guidelines in oncology.
JNCCN Journal of the National Comprehensive Cancer Network.
2015
Review
GET IT
Times cited: 22 -
Candidate genetic modifiers for breast and ovarian cancer risk inBRCA1andBRCA2 mutation carriers.
Cancer Epidemiology Biomarkers and Prevention.
2015
Academic Article
GET IT
Times cited: 14 -
Genetic/familial high-risk assessment: Breast and ovarian, version 1.2014.
JNCCN Journal of the National Comprehensive Cancer Network.
2014
Review
GET IT
Times cited: 77 -
Breast cancer phenotype in women with TP53 germline mutations: A Li-Fraumeni syndrome consortium effort.
Breast Cancer Research and Treatment.
2012
Academic Article
GET IT
Times cited: 82 -
Challenges to the development of new agents for molecularly defined patient subsets: Lessons from BRCA1/2-associated breast cancer.
Journal of Clinical Oncology.
2011
Academic Article
GET IT
Times cited: 16 -
Breast cancer risk reduction.
JNCCN Journal of the National Comprehensive Cancer Network.
2010
Review
GET IT
Times cited: 22 -
Genetic/familial high-risk assessment: Breast and ovarian - Clinical practice guidelines in oncology™.
JNCCN Journal of the National Comprehensive Cancer Network.
2010
Review
GET IT
Times cited: 166 -
Breast cancer screening and diagnosis: Clinical practice guidelines in oncology™.
JNCCN Journal of the National Comprehensive Cancer Network.
2009
Review
GET IT
Times cited: 225 -
Hereditary cancer predisposition syndromes.
Journal of Clinical Oncology.
2005
Review
GET IT
Times cited: 335